药物侵入性策略与半剂量重组的人类益洛基纳酶与初级皮肤冠状动脉干预相比
Chao Jiang1, Jie Dou1, Huihui Yang1
1School of Medicine, Chengde Medical University, Chengde, Hebei, China.
Anatolian journal of cardiology
|March 4, 2025
概括
使用半剂量前激素酶 (PHDP) 的药物侵袭策略显示,对于ST升高心肌梗塞 (STEMI) 患者,其疗效与初级穿皮冠状动脉干预 (PPCI) 相似. 此外,PHDP还减少了与程序相关的并发症,使其成为可行的替代性再输注策略.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 紧急医疗 紧急医疗
背景情况:
- 初级穿皮冠状动脉干预 (PPCI) 是对ST段升高心肌梗塞 (STEMI) 的标准反疗法.
- 目前正在研究替代的再注射策略,以改善结果和可访问性.
研究的目的:
- 在STEMI患者中,与PPCI相比,使用半剂量复合人体前激酶 (PHDP) 的药物侵入性策略的疗效和安全性进行评估.
- 确定PHDP是否提供类似的再输血率并减少与程序相关的并发症.
主要方法:
- 一项随机试验将PHDP (早期纤维解与及时导管) 与PPCI在18-80岁的STEMI患者中进行比较,这些患者在症状出现后24小时内出现.
- 主要终点包括TIMI流量等级3,TIMI perfusion等级3和ST段分辨率≥70%干预后一个小时.
主要成果:
- 在PHDP和PPCI组之间,初级再输血终点没有显著差异.
- 在PHDP组中,慢流/无反流,恶性心律不整以及低血压的发生率显著降低.
- 与PPCI组相比,PHDP组的30天组合不良结果较少 (P = .032).
- 没有报告在医院内内出血或重大出血事件;轻微出血率相似.
结论:
- 使用半剂量前激素酶 (PHDP) 的药物侵入性策略在24小时内出现STEMI患者的上心和心肌再注射中显示出与PPCI相似的疗效.
- 与PPCI相比,PHDP与流程相关并发症的风险降低有关.
- 需要进行进一步的临床试验,研究用半剂量纤维素溶解剂的药物侵入性策略.
更多相关视频
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
1.4K
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
11.8K
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454